
Renew Biopharma
Biotechnology, Sorrento Vly Rd, San Diego, , 92121, California, 11555, United States, 1-10 Employees
Phone Number: 85********
Who is RENEW BIOPHARMA
Renew has developed a novel enzymatic platform by synthetic biology to create a diverse pipeline of proprietary therapeutic molecules (i.e. alkylresorcinol scaffold derivatives; similar t...
Read More

-
Headquarters: 11555 Sorrento Vly Rd, San Diego, California, 92121, United States
-
Date Founded: 2016
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 7389
Does something look wrong? Fix it. | View contact records from RENEW BIOPHARMA
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Renew Biopharma
Answer: Renew Biopharma's headquarters are located at Sorrento Vly Rd, San Diego, , 92121, California, 11555, United States
Answer: Renew Biopharma's phone number is 85********
Answer: Renew Biopharma's official website is https://renewbiopharma.com
Answer: Renew Biopharma's revenue is $1 Million to $5 Million
Answer: Renew Biopharma's SIC: 7389
Answer: Renew Biopharma has 1-10 employees
Answer: Renew Biopharma is in Biotechnology
Answer: Renew Biopharma contact info: Phone number: 85******** Website: https://renewbiopharma.com
Answer: Renew has developed a novel enzymatic platform by synthetic biology to create a diverse pipeline of proprietary therapeutic molecules (i.e. alkylresorcinol scaffold derivatives; similar to CBGA). Uniquely, Renews scaffold molecules pass the blood brain barrier and engage a classic cellular receptor that controls inflammation (i.e. PPAP), together making this family of molecules particularly useful for indications of neuro-therapeutics. Renew is specifically focused on developing therapeutics to treat neuroinflammation pathologies, with specific focus on Traumatic Brain Injury (TBI). No drug treatment is currently approved by the FDA for TBI, while millions of patients from all age groups are effected worldwide annually. Renews proprietary enzymatic chemistry processes are in stark contrast to traditional medicinal chemistry processes commonly employed by Big Pharma. While traditional medicinal chemistry often requires noxious reaction components and exhibits low synthesis efficiencies, Renews custom engineered enzymatic reactions are highly efficient and scalable. These enzymatic reactions are particularly amenable for alkylresorcinol scaffold derivative molecules (that require prenylation-type synthesis). Renews platform for creating therapeutic derivatives by engineered enzymes is covered by a robust IP portfolio related to key enzymes (and engineered variants thereof) for production of alkylresorcinol derivatives by prenylation processes.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface

Sign in to CIENCE GO Data to uncover contact details
Free credits every month